SCHEMBL7147764

SCHEMBL7147764

O=Cc1cc(OCc2ccccc2Cl)ccc1OCc1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.51
NR4A2 P43354 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HRH3 Q9Y5N1 1/20 0.49
MAOB P27338 3/20 0.49
MAOA P21397 1/20 0.49
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TUBB1 Q9H4B7 1/20 0.46
PTP4A3 O75365 1/20 0.45
PTPN1 P18031 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30679631 0.84 PTP4A3 (0.60) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL15619523 0.83 HPGD (0.66) MAPTHPGDKDM4EALDH1A1LMNA
SCHEMBL3615463 0.79 MAOB (0.58) MAPTNPC1RAB9AMAOBMAOA
SCHEMBL3267315 0.78 HPGD (0.49) MAPTHPGDNR4A2NPC1RAB9A
SCHEMBL8422956 0.77 NR4A2 (0.60) MAPTHPGDNR4A2NPC1RAB9A
SCHEMBL7150750 0.77 TUBB1 (0.55) MAPTNR4A2NPC1RAB9AMAOB
SCHEMBL8985589 0.77 NPC1 (0.68) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL7150434 0.76 MAOB (0.60) NR4A2MAOBMAOATUBB1
SCHEMBL31384429 0.76 NPC1 (0.51) MAPTHPGDNR4A2NPC1RAB9A
SCHEMBL7170719 0.76 NR4A2 (0.71) MAPTNR4A2NPC1RAB9AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA MAPT 3924/4885HPGD 2167/4885NR4A2 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.